<![CDATA[Transfusion-transmitted-infection (TTI) screening is an important process in blood banks to minimize the risk of transmission during transfusion. To date, the primary pathogens screened for TTIs include hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and Treponema pallidum (syphilis). Currently, serology is still most widely used in Indonesia. Nucleic acid test (NAT) has been used in developed countries due to earlier detection and greater sensitivity compared to serology. Several reports found discrepancies between NAT and serology. Indonesia widely uses serology and is beginning to use NAT for TTI screening. To analyze the correlation and discrepancy between chemiluminescence Immunoassay (CLIA) and NAT in TTI screening. This retrospective study included all donor samples evaluated for serology and NAT as part of TTI screening between May and December 2024. Serology used Abbott Alinity, while NAT used Procleix with screening reagents. Positive results were verified by NAT with specific reagents. This study included 6,335 samples: 6,320 (99.76%) were negative for both methods, 2 samples (0.03%) were positive for both methods, and 13 samples (0.21%) showed a discrepancy. The correlation study showed a significant result (p <0.001). Positive serology and negative NAT were found in 8 samples (0.13%) with low reactive indices. Final result after verification with confirmation NAT showed that all samples were negative. Negative serology and positive NAT were found in 5 samples (0.08%), which confirmed 3 positives for hepatitis B, 1 for HIV, and 1 negative result. This study showed a concordance rate of 99.79% between serology and NAT. Utilizing serology in parallel with NAT in TTI screening will be beneficial.]]>
Copyrights © 2026
